questionable data

Exclusive: Questionable Data Propped Up Cancer Drug Provenge

Exclusive: Questionable data propped up cancer drug Provenge

Filed under: drug treatment news 2010

The U.S. Food and Drug Administration also stood by its April 2010 decision to approve the treatment. But the disclosure could mark another setback for Dendreon, whose market value has tumbled over 70 percent in the past eight months after …
Read more on Chicago Tribune

 

Novartis drug Gilenya shows significant early effect on reducing brain volume

Filed under: drug treatment news 2010

Vol.362 No.5, Feb 4, 2010;362:402-415.7.Havrdov¡ E. et al. Clinical outcomes in subgroups of patients with highly action relapsing-remitting multiple sclerosis treated with Fingolimod (FTY720): Results from the FREEDOMS and TRANSFORMS phase III …
Read more on MENAFN.COM

 

With rise in prescription drug use comes greater addiction

Filed under: drug treatment news 2010

That pattern follows statewide and national trends, trends coupled with rising numbers of people seeking treatment for prescription drug addiction. The sales of prescription opioid pain relievers nationwide ballooned between 1999 and 2010. The Centers …
Read more on Times Herald-Record

 

More drug treatment news 2010 Resources

Images of Exclusive: Questionable data propped up cancer <b>drug</b> Provenge” title=”Images of Exclusive: Questionable data propped up cancer <b>drug</b> Provenge” /></a> </p>
<p style=News Exclusive: Questionable Data Propped Up Cancer Drug Provenge
NEW YORK (Reuters) – In Dendreon Corp's most important clinical trial for the controversial cancer therapy Provenge, researchers analyzed some of the data differently from how the company told U.S. regulators they would, according to documents reviewed by Reuters. That not only was a departure from scientific norms, but also artificially inflated the apparent benefit of the prostate cancer … Read News

Wikipedia Sipuleucel-T – Wikipedia, The Free Encyclopedia
cancer staging designation is T4,N1,M1c. First FDA-approved cancer vaccine. Sipuleucel-T was approved by the U.S. Food and Drug There have been criticisms of the clinical trial data supporting the efficacy of Provenge that should This theory was brought up at the CMS Advisory Committee Meeting … Read Article